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EXECUTIVE SUMMARY 
In January 2002, the Commission adopted a Strategy for Europe on Life Sciences and 
Biotechnology consisting of two parts – policy orientations and a 30 point plan to transform 
policy into action.  
The Commission intends to report regularly on the progress made in implementing this 
Strategy. It states what has been achieved in policy development and on the ground, 
anticipates emerging issues - namely tissue engineering, genetic testing and animal 
biotechnology – and indicates elements of a policy response. It also incorporates, to the 
largest possible extent, the elements listed in the roadmap within the conclusions adopted by 
the Competitiveness Council of 26 November 2002. It is supported by a Commission Staff 
Working Paper providing further detailed information and timing on implementation of the 
action plan. 
Since last year’s report was issued, further progress has been made in the implementation 
of the Strategy …….. 
The 6
th Framework Programme for Research (FP6) provides a major incentive for research in 
this area. The Commission, together with all other interested stakeholders, has continued its 
effort to bring science and society closer together and to develop an understanding of and an 
information exchange on life sciences and biotechnology. The review of the pharmaceutical 
legislation was adopted early this year. The regulatory framework on Genetically Modified 
Organisms has been completed and guidelines on co-existence in agriculture have been 
published.  
Member States have chosen different strategies to provide the policy underpinning of biotech 
development and have opted for different instruments to support biotechnology development. 
They have also responded effectively to the challenge of education. Most have revamped the 
life sciences curricula and added new courses and material. Several Member States have in 
addition established relationships between academia and industry/society. 
There are also a number of actions in the Member States intended to obtain “brain-gain” by 
making the European Research Area (ERA) more attractive for scientists in and outside the 
Union. 
…However, there is obviously still much to be done to improve the situation for European 
biotechnology.  
Public and private investments in research urgently needs to be increased. There is a need 
to continue to improve biotechnology companies’ access to finance. The number of 
European companies has remained stable, while the number of pharmaceutical compounds in 
clinical trials (a common measure of research activity) has continued to increase. This 
growing maturity of the industry will put much higher demands on the European system for 
financing innovation and growth than was previously the case. 
Member States still need to make progress on the implementation of measures to which they 
are already committed. One major example is intellectual property. The delays incurred in 
the  implementation of Directive 98/44/EC, on the legal protection of biotechnological 
inventions leaves companies engaged in innovative biotechnology research uncertain as to 
whether they are fully entitled to the commercial fruits of their work. This is severely 
hampering the industry's development, discouraging not only innovators themselves but also  
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the potential investors whose finance is so desperately needed. The slow progress in adopting 
a Community patent has also led many companies to adopt a strategy of primarily securing 
patents in the US and a few European states. Resolving these two issues will be important for 
the growth of the biotechnology industry. 
More active co-operation from all Member States is also needed in the implementation of 
the new legislation governing GMOs. Having demanded—and subsequently committed 
themselves to—a more rigorous framework, it is now imperative that all Member States 
implement the basic Directive 2001/18/EC on the authorised release of GMOs into the 
environment and the two regulations on traceability/labelling and GM/food and feed.  
The next stage in the strategy is for the various authorities and organisations to make 
commitments and to begin delivering the new policy measures according to the 
responsibilities set out in the action plan.  
The Commission is directly responsible for some actions but it is also determined to do what 
it can to keep up the general momentum and to play a facilitating role.  
Against the background of the renewed political debate on the Lisbon agenda of task to 
revamp Europe’s competitive position, there is an acknowledged need to step up the measures 
to meet the Lisbon commitments. The Biotechnology Strategy includes many subjects and 
stakeholders and the Union has to ensure that the coherence of its efforts is maintained. This 
calls for a greater coordination and cooperation between Member States and the 
Commission, with the aim of improving Europe’s competitiveness. Consequently, the 
Commission proposes to reinforce the role of the existing Biotechnology network with 
Member States.  
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1.  INTRODUCTION 
In January 2002, the Commission adopted a Strategy for Europe on Life Sciences and 
Biotechnology.
1 This sets out a comprehensive roadmap up to 2010 and puts the sector at the 
forefront of those frontier technologies which should move the European Union towards its 
long-term strategic goal established by the Lisbon European Council in March 2000. 
This strategy set by the Commission consisted of two parts – policy orientations and a 30 
point plan to transform policy into action. It sets out what was needed from the Commission 
and the other European Institutions, while also recommending actions for other public and 
private stakeholders. 
The Commission intends to report regularly on the progress made. On 5 March 2003, the 
Commission adopted its first progress report
2, highlighting  the progress made but also 
pointing out delays in some areas. It invited Member States to provide the necessary impetus 
to carry the strategy forward. 
This Communication is the second such response. It states what has been achieved in policy 
development and on the ground, and anticipates emerging issues. It also incorporates to the 
largest possible extent the elements listed in the roadmap within the conclusions adopted by 
the Competitiveness Council of 26 November 2002.  
As last year, this report is supported by a Commission Staff Working Paper providing further 
detailed information and timing on the implementation of the action plan. 
2.  REACTION TO THE COMMISSION’S FIRST PROGRESS REPORT 
While highlighting the progress made in the implementation of the Strategy, the Commission 
pointed out in its first progress report that the picture was more mixed in some areas and was 
already giving cause for concern. This was down to the need for more research and 
financial resources, the need to complete the system of Intellectual Property protection 
and the delay in the areas of GMOs. The Commission concluded by calling on Member 
States to develop a clearer and more consistent policy on biotechnology to avoid the risk of 
reducing the impact, effectiveness and coherence of the EU’s strategy in this field.  
In its opinion of 16 July 2003, the European Economic and Social Committee shared the 
Commission’s views, noting with a degree of pessimism that the Member States have not 
taken sufficient steps to swiftly achieve the goals laid down in the conclusions adopted by the 
Competitiveness Council on 26  November 2002. It asked the Commission to include a 
detailed analysis of achievements, failings and delays with respect to the approved plan in the 
next annual report. 
At the Competitiveness Council of 22 September 2003, EU Ministers welcomed the first 
progress report on the implementation of the European Biotechnology Strategy and agreed 
with the broad lines of its analysis and adopted a set of conclusions. 
                                                 
1 COM(2002)27  final. 
2  COM(2003)96 final. It was supported by Commission Staff Working Paper SEC(2003)248  
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The Council 
–  stressed the need for “significant efforts to be made to move from the 
conceptual and planning stage to the implementation of the Strategy and of 
the roadmap contained in the Council conclusions of 26 November 2002 in 
order to contribute effectively to the achievement of the EU competitiveness 
objectives set by the Lisbon European Council, 
–  encouraged Member States and the Commission to step up their co-
operation and to regularly exchange information on progress made in order 
to advance in the priority areas for future action already identified and, in 
particular, to improve conditions for access to finance for biotechnology 
companies and to complete and implement the general regulatory 
framework. 
The European Convention on Life Sciences and Biotechnology organised by the Italian 
Presidency on 21-22 November 2003 further stressed the need for greater cooperation 
amongst various parties and for better co-ordination to be achieved in the national policies of 
Member States. 
Priorities for future actions 
Commission and Member States 
►  to increase their co-operation and exchange of information in order to enhance coherence and 
disseminate best practices. To this end, reinforcement of the existing Biotechnology network with 
Member States should be considered. 
3.  OVERVIEW OF POLICY DEVELOPMENTS AND PRIORITIES FOR ACTIONS 
3.1.  Harvesting the potential 
Competitiveness of European biotechnology sector and related industries 
The biotechnology industry world-wide has continued to develop, although at a slower rate 
than previously due mainly to the lower confidence of investors in high-technology sectors 
since 2000. However, there seems to have been some recovery in biotechnology in 2003, 
particularly in the US but increasingly also in Europe.  
The number of European companies has remained stable, while the number of pharmaceutical 
compounds in clinical trials (a common measure of research activity) has continued to 
increase. This growing maturity of the industry will put much higher demands on the 
European system for financing innovation and growth than was previously the case. The slow 
progress in adopting a Community patent has also led many companies – specifically SMEs- 
to adopt a strategy of primarily securing patents in the US and a few European states. 
Resolving these two issues will be important for the growth and competitiveness of the 
biotechnology industry. 
As highlighted in a recent letter of Prime Minister Tony Blair, President Jacques Chirac and 
Federal Chancellor Gerhard Schröder in anticipation to the 2004 Spring Council, life sciences 
and biotechnology are amongst the key growth technologies for a more innovative and  
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competitive Europe. Critical to the success of the innovation process is the ability of business 
to transform research initiatives into commercially viable processes and products. 
It is well known that Europe has more biotechnology companies than the US. It is also often 
repeated that the US industry employs far more people and has a much higher turnover. A 
more careful analysis highlights some interesting aspects of this seeming paradox.  
The innovative and economic performance of small European biotechnology companies is 
comparable to their US counterparts. There does not seem to be any fundamental limitations 
on European companies at that level. Interestingly enough, neither does there seem to be 
much difference in the performance of medium-size companies. Europe does however have 
far fewer of those companies compared to the US. Undoubtedly, this can partly be ascribed to 
Europe’s younger industry, but there are clear indications that difficult access to later-stage 
finance and the absence of liquid stock markets for technology shares have contributed.  
As noted in the Strategy, there is a strong potential for the use of biotechnology in industrial 
processes and new materials. This so called “white biotechnology” may well represent a 
significant portion of the whole biotechnology industry in the coming years, but is also a 
sector where European companies hold a strong position. One of the main challenges to 
European policy-makers will be to put the conditions in place to ensure that bio-based 
solutions become mainstream options for industrial development. 
Member States have chosen different strategies to provide the policy underpinning of biotech 
development. In Finland a ministerial working group coordinates the work while in other 
Member States the task is done by individual ministries or through government agencies.  
In similar fashion, Member States have chosen different instruments to support biotechnology 
development. Some have introduced fiscal benefits or deferred social security payments 
(France, Italy), some are encouraging inward investment (Ireland, Spain), yet others stress 
technology transfer (Italy). There is no single measure that is universally applicable, but 
continuing exchanges of views and collaboration will help to policymakers to choose the mix 
of measures that is most beneficial given the local circumstances. 
Member States have also responded effectively to the challenge of education. Most have 
revamped the life sciences curricula and added new courses and material. Several Member 
states have in addition established relationships between academia and industry/society. It is 
likely that there is much to be learned from an exchange of experiences. 
There are also a number of actions in the Member States intended to obtain “brain-gain” by 
making the European Research Area more attractive for scientists in and outside the Union. 
Tax treatment and better conditions for leading edge research are being introduced in Austria, 
Denmark, Germany, Italy and other Member States. 
The Competitiveness in Biotechnology Advisory Group 
In accordance with Action 10b of the Strategy, in 2003 the Commission appointed  a 
Competitiveness in Biotechnology Advisory Group with Industry and Academia (CBAG). 
It gathers representatives from all the various industry segments and from companies at every 
stage of company development together with entrepreneurial academics and has the role of 
issuing recommendations to the Commission and contributing to this annual report. In its first 
report, the group chose to concentrate on the issues of access to finance and regulation.   
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The Group highlighted that entrepreneurial biotechnology companies are faced with the same 
pressures as other innovative companies, except that for biotech companies these pressures 
are often more acute. It identified three main areas that require attention to boost the 
financial environment for biotech companies, namely 
¾  protecting intellectual property rights, 
¾  boosting finance, liquidity and capital markets in Europe, and  
¾  research funding through public/private partnerships. 
The Group stressed that, for fast and effective improvements, the entrepreneurial 
biotechnology community expects policy changes mainly at national level rather than at EU 
level. Therefore, many of its recommended actions target Member States rather than the 
Commission. 
The full text of the Group’s report can be found in the Commission staff working paper. 
Intellectual property protection 
The CBAG calls for a speedy and full implementation and application of adopted 
Community legislation and criticises the delays in some Member States in transposing already 
agreed legislation, in particular the Biotechnology Patent Directive. The Group recommends 
enhanced communication between regulatory authorities and between such authorities 
and applicants. 
After receiving the opinion of the European Parliament, the Commission proposal for a 
Regulation on the Community Patent
3 is being discussed in the Council, where, on 3 March 
2003, a common political approach was agreed on a number of issues. This approach provides 
useful guidance for the finalisation of the regulation. 
To date, only seven Member States
4 have transposed Directive 98/44/EC
5 on the legal 
protection of biotechnological inventions into their national legal systems while the other 
Member States are currently at varying stages of progress. On 9 July 2003, the Commission 
referred the other eight Member States to the European Court of Justice for their failure to 
transpose the Directive into their national legislation. The lack of transposition of the 
Directive leaves companies engaged in innovative biotechnology research uncertain as to 
whether they are fully entitled to the commercial fruits of their work. This is severely 
hampering the industry's development, discouraging not only innovators themselves but also 
the potential investors whose finance is so desperately needed. 
For its part, the Commission has considered two questions identified in the Annual Report of 
the Commission to the European Parliament and the Council on the development and 
implications of patent law in the field of biotechnology and genetic engineering provided for 
by Article 16(c) of Directive 98/44/EC
6, namely the scope of patents relating to sequences or 
part-sequences of genes isolated from the human body, and the patentability of human stem 
cells and cell lines obtained from them. 
                                                 
3 COM(2000)412. 
4  Denmark, Finland, Ireland, United Kingdom, Greece, Spain and Portugal. 
5  OJ L 213, 30.7.1998, p.13. 
6  COM(2002)545 final, 7.10.2002.  
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These two topics have been studied and analysed by a group of independent experts. The 
Commission is drafting the second report provided for in Article 16© of the directive, taking 
into account the comments made by the experts. 
Priorities for future actions 
Council 
►  to resolve the remaining difficulties following the political agreement of 3 March 2003, and to adopt 
the Community Patent Regulation in 2004, 
►  to take a decision in good time on the creation of the centralised Community patent court, for 
which the Commission has presented a proposal
7 to the Council in December 2003, 
►  to agree on changes to the European Patent Convention in order to allow the European Patent 
Office to grant Community Patents. 
Member States 
►  to fully and swiftly transpose and implement Directive 98/44/EC. 
Access to finance 
The biotechnology industry, with its long development times and high costs, is uniquely 
dependent on effective access to finance. 
The CBAG stresses that lack of capital and the fragmentation of the European securities 
markets is impeding the industry’s development and recommends swift harmonisation of 
securities regulations, to enable multiple listings and mergers of markets. The Group agrees 
with the conclusions of the Biotechnology and Finance Forum as mentioned below and 
recommends the establishment of funds to cover the gap between traditional venture 
capital (VC) financing and the IPO stage. 
In general, the financial community has retained confidence in the industry, but in 2002-2003 
the overall retrenchment of risk capital and the arrival of a large number of companies at the 
point where they need new financing to continue their expansion combined to threaten a 
substantial segment of the industry.  
This problem first surfaced in countries, such as Germany, where the success of the BioRegio 
programme in the nineties had led to a large number of companies at the same stage of 
development, but other Member States where the industry has made a significant start shortly 
face the same problem. It should be noted that the present problem is a consequence of the 
large-scale success in developing an industry, not of failure  
The Commission’s advisory Biotechnology and Finance Forum, reporting early in 2003 on 
the issue, identified a number of problems and several Member States and the European 
financial institutions have worked to find appropriate solutions.  
Germany and the European Investment Fund (EIF) have created a common fund to tackle this 
acute situation, while other Member States, such as France have acted by reviewing their 
fiscal and social contributions policies. In October 2003 the European Investment Bank (EIB) 
decided to commit half a billion € for the EIF to invest in funds in high-technology 
                                                 
7  COM(2003)827 and 828  
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companies. This measure can be expected largely to benefit biotechnology companies. The 
EIF investment rules have also been changed to allow investments in later stage 
entrepreneurial companies. This provision is of great importance given the long development 
times of most biotech products. 
The biotechnology industry will always be characterised by the creation and disappearance of 
entrepreneurial companies, but it may be hoped that the recent measures will help to retain 
companies with good products and good management that would otherwise find the situation 
impossible. This is of vital importance to the consolidation and development of an industry 
with a critical mass also composed of medium-size companies. 
Networking Europe’s biotechnology 
Fragmentation is still a crucial issue for Europe’s biotechnology stakeholders. There is still 
too little cross-national collaboration between researchers and companies, and too little 
awareness of developments in other European countries. There are many regional 
biotechnology clusters, although co-operation between them is under-developed; this is a 
particular problem considering that many of them lack critical mass. 
In consequence, networking is vital for the effective further development of biotechnology in 
Europe. The Commission is supporting the creation of an external European Biotechnology 
Web Portal, with the aim to successfully link up companies, the academic world and 
interested lay people. The portal will be available in 2004. 
The informal network with Member States officials on competitiveness issues, established 
in accordance with action 10a of the Strategy, is operating successfully and has now been 
expanded to the accession countries. This network will play an important role in the 
benchmarking of European Biotechnology Policies that has just been launched and has 
already made a constructive contribution to the previously mentioned finance issue. 
Priorities for future actions 
Commission and Member States 
►  to develop, in 2004-2005, a benchmarking programme as a tool for policymakers to develop the 
right mix of policies, given their Member State’s circumstances, and to repeat the benchmarking at 
intervals to provide a basis for an exchange of best practices and fine-tuning of policies. 
Research and Technological Developments 
In its report to the Spring European Council
8, the Commission indicated that the Union is still 
far from achieving the objectives set at the Lisbon European Council. An analysis of progress 
has highlighted the lack of investment in knowledge sectors, namely research, innovation, 
education and training. High priority should now be given to improving the framework 
conditions and public support for research investment and ensuring consistency and synergy 
in Europe through the open method of co-ordination.  
This requires a determined and co-ordinated efforts by all interested parties - EU Member 
States and public and private sector stakeholders - to implement the Investing in Research 
action plan
9 setting out initiatives to give Europe a stronger public research base and to make 
                                                 
8  COM(2004)29 final, Delivering Lisbon: Reforms for the enlarged Union 
9  COM(2003)226 final, Investing in research : an action plan for Europe  
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it much more attractive to private investment in research and innovation. Key actions include 
setting up European technology platforms, strengthening links between industry and public 
research, redirecting public spending towards research and innovation, making research 
careers more attractive and developing better fiscal incentives for research. 
Priorities for future actions 
Member States, public and private sector stakeholders 
►  to implement the action plan “Investing in Research”. 
Funding research in Europe 
For its part, the Commission has enhanced its support for Life Sciences and Biotechnology 
research under the 6
th Framework Programme for Research (FP6). Implementation of this 
Programme has in fact increased the Commission’s financial contribution to research in this 
area by some 20% compared with the 5
th Framework Programme for Research. As a result of 
the first call for proposals more than €810 million was allocated to actions in the 2 thematic 
priorities “Life sciences, genomics and biotechnology for health” and “Food Quality and 
Safety”, mobilising more than 2700 laboratories, including about 400 SMEs. 
Disciplines are converging and life sciences and biotechnology are now permeating many 
areas of research including nanotechnology, informatics, social sciences and engineering. 
Therefore, other thematic priorities such as Nanotechnology, Sustainable Development, 
Citizen and Governance as well as research in ethics under Science and Society, will 
contribute to generating progress in life sciences and biotechnology. 
Funding has been concentrated on a few selected priorities and the new funding instruments 
(Network of Excellence and Integrated Projects) provide top researchers with a critical mass 
of resources and skills to be at the leading edge of science and technological developments. 
The new instruments foster linkage between basic scientists and clinicians, between academia 
and industry, between disciplines (physicists, geneticists, computer scientists, etc.), involving 
both the natural sciences and experts in ethics and social sciences, and between the scientific 
communities and consumer and patient organisations, etc. The goal of stimulating these 
interactions is not unique to Europe, but the European experience may benefit the 
international scientific community and serve as a model for other nations.  
As a result of the first call for proposals, about 10% of the budget (approximately €80m) will 
be allocated to SMEs. In addition, 52 Specific SME activities (Co-operative Research, 
Collective Research) and research and innovation activities (Economic and Technological 
Intelligence actions) will be implemented to help a large community of SME’s develop 
innovation in healthcare, food quality and safety, agriculture and aquaculture. 
In order to improve the access to biological resources and large-scale high technology 
facilities essential for both the research and commercial development of biotechnology, 
actions on access to research infrastructures are supported under the specific programme 
"Structuring the European Research Area" (2002-2006) (EU contribution of €48.7m). 
Amongst the numerous areas holding much potential in the area of Life Sciences and 
Biotechnology, the following are being promoted:  
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¾  Genomics research 
The  BioSapiens Network of Excellence brings together 24 bioinformatics centres in 14 
countries throughout Europe. Bio Sapiens aims to address the current fragmentation of 
European bioinformatics by creating the “European Virtual Institute for Genome 
Annotation”
10. The Institute will establish a permanent European School of Bioinformatics. 
¾  Biotechnology for health 
As one of the measures geared towards the European Research Area (ERA), the Commission 
has called together the Forum of Genomes Programme Managers to help find synergies 
between national research activities in the field of genomes research in Europe. 
CO-ORDINATION OF GENOMES RESEARCH ACROSS EUROPE ( COGENE) 
COGENE
11 aims to promote the development of synergies between national genome research 
programmes related to human health in Europe. It acts on behalf of the Forum of Genomes 
Programme Managers with representatives from 25 European countries. At the moment COGENE is 
mapping major national research funding sources and the most important infrastructures for genomes 
research within the COGENE forum member countries. COGENE workshops, which brought together 
research managers from national funding agencies, academia and industry, have yielded 
recommendations for further actions to co-ordinate research in strategically important fields, such as 
pharmacogenomics and population genomics. 
 
¾  Plant genomics and biotechnology 
Although progress on GMO’s has been made in recent years and new non-GM technologies 
(e.g. marker-assisted breeding and high-throughput identification of mutations in genes of 
interest) are being developed and applied, it will take a joint effort on the part of all 
stakeholders to regain ground in plant science and strengthen the competitive position of EU 
research and industry in the world. 
The Integrated Project “New strategies to improve grain legumes for food and feed”, involving 
52 participants from 18 countries, will mobilise and integrate European scientific research on 
grain legumes (e.g. peas, lupins, lentils, chick peas) in particular it will contribute to the 
sequencing of the genome of the model legume M. truncatula and generate extensive 
functional genomics tools for M. truncatula as well as for grain legumes of economic 
importance for Europe. In yet another step towards creating a true European Research Area, 
the Commission is also supporting an ERA-NET on Plant Genomics
12 aimed at coordinating 
the national research programmes in this area of ten EU member states and Norway. 
This ERA-NET is expected to be an important part of a future European technology 
platform on plant genomics and biotechnology, which is currently being set up. The aim of 
this platform is to develop an EU-wide strategy to re-build and strengthen the S&T base in 
plant genomics and biotechnology, taking into account the needs of the different industrial 
sectors (food, chemicals, pharmaceuticals etc.). The platform will involve key stakeholders 
from research, biotech, - food and feed- industry, farmers, regulators and consumers. Based 
                                                 
10  ‘Annotation’ is the process by which features of the genes or proteins stored in a database are extracted 
from other sources, defined and interpreted. 
11 http://www.cogene.net 
12 http://www.cordis.lu/coordination/era-net.htm  
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on a common vision for the development of plant genomics and biotechnology in Europe, one 
of the key objectives of this platform will be to formulate a strategic research agenda for 
2005-2010 defining, for both medium and long-term targets, priorities, and building up the 
necessary public-private-partnership, including the mechanism to mobilise private and public 
investments which will be required for the implementation of the research and development 
strategies. 
Priorities for future actions 
Commission 
►  to launch the European technology platform on plant genomics and biotechnology in Spring 2004. 
Industrial biotechnology 
The potential of industrial biotechnology in terms of competitiveness, growth and 
environmental sustainability has been reflected in a series of OECD reports
13. Despite the 
funding of this area under the various EC Framework Programmes and strategic research 
programmes in a number of Member States, large scale practical applications of industrial 
biotechnology in Europe seem to be limited, while in the US and in Japan a strategic research 
agenda for the development of industrial biotechnology has been formulated. 
The importance of industrial biotech for sustainable development has been highlighted in the 
recent Commission Communication on “Environmental Technology Action Plan”
14. 
Priorities for future actions 
Commission 
►  to launch a series of roundtables in Spring 2004 bringing together stakeholders from research, 
industry, NGOs, regulators and representatives from Member States with the aim to prepare by 
mid 2004 a vision paper for European industrial biotechnology. 
Human resources in R&D: Researchers 
Human resources are vital to R&D. The need to take action has been acknowledged. The 
Commission has taken a proactive role, from promoting and financing several initiatives to 
attempting to streamline legislations, in an attempt to improve the researchers’ environment 
and to make the European Research Area more attractive to scientists in and outside the 
Union. As part of the implementation of the Mobility Strategy for the European Research 
Area
15, the Commission has launched several initiatives, in close cooperation with the 
Member States, including the “The Researcher’s Mobility Portal”
16, which provides web-
based national and Community information on a European scale, specific job and fellowship 
opportunities for researchers, and the European network of mobility centres( ERA-
MORE) which will provide researchers and their families with customised assistance in all 
matters relating to their working and daily lives when undertaking a mobility experience. 
                                                 
13  E.g. "Biotechnology for Clean Industrial Products and Processes: Towards Industrial Sustainability", 
1999; and "The Application of Biotechnology to Industrial Sustainability", 2001; OECD, Paris. 
14  COM(2004)38 final “Stimulating Technologies for Sustainable Development: An Environmental 
Technologies Action Plan for the European Union.( http:\\europa.eu.int/comm/environment/etap)  
15  (COM(2001)331 final of 20.06.2001) 
16  http://www.europa.eu.int/eracareers  
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The budget for the Structuring Activity “Human resources and mobility” under the 6
th 
Framework Programme for Research has been almost doubled from the 5th Framework 
Programme value
17. Research training opportunities in Europe for researchers have been 
reinforced. Specific grants providing return opportunities for those European researchers who 
have spend long periods outside Europe as well as International Marie Curie Fellowships 
and Marie Curie Excellence Grants and Chairs to attract world-class researchers to Europe 
have been introduced. As a result of the first calls for proposals €47 million (13% of the 
budget) has been allocated to “Human resources and mobility”/”Marie Curie” actions in Life 
Sciences and Biotechnology. 
In its Communication  “Researchers in the European  Research Area: one profession, 
multiple careers”
18, the Commission addresses for the first time at European level the issue 
of the researcher profession and researchers’ careers. 
A proposal for a Directive on the entry and stay of third country researchers within the EU 
and an associated action plan was adopted by the Commission on 16 March 2004
19. 
The Commission is launching a series of initiatives, which will be implemented in the course 
of 2004, in order to open a structured dialogue between the different stakeholders. 
Priorities for future actions 
Commission 
►  to propose Recommendations on a “European Researcher’s Charter”, a framework for the 
career management of human resources in R&D, based on voluntary regulation, as well as on a 
“code of conduct for the recruitment of researchers” to improve recruitment methods, and to 
launch studies to assess and benchmark the multiple career paths of researchers. 
Future Research Policy Initiatives 
The Commission is now starting to reflect on the design of the next European Research 
Framework Programme. A vision for future research activities is vital in order to maintain and 
increase momentum towards an effective knowledge-based economy and society. Taking 
current initiatives as a basis and identifying the needs and expectations of the scientific 
community, policy-decision-makers and society, an orientation document will be presented to 
initiate a debate engaging all stakeholders. 
Priorities for future actions 
Commission 
►  to present a Communication regarding future research policy initiatives in May 2004. 
►  to prepare a revision of the Community framework on state aid for R&D. 
                                                 
17  Human capital web site: http://www.europa.eu.int/comm/research/fp6/mariecurie-actions/home_en.html 
18 COM(2003)436  of  18.07.2003 
19 COM(2004)178  final  
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3.2.  Governing life sciences and biotechnology 
Social scrutiny and dialogue 
Uncertainties about social acceptance of biotechnology have continued to weaken the EU’s 
capacity for innovation. With the exception of medical applications, public expectation of 
biotechnology, with particular reference to agricultural applications, remains moderate. 
Therefore, the Commission, together with all interest stakeholders, has continued its efforts to 
bring science and society closer together and to develop an understanding of and information 
exchange on life sciences and biotechnology. However, it is imperative that industry should 
openly explain and document the benefit and potential of this technology in all its fields of 
application, and the initiatives to a broader dialogue by the industry and by the European 
Federation of Biotechnology are to be welcomed. 
As envisaged in Action 13(a) of the Strategy, the Commission organised the first stakeholder 
conference entitled “Risk perception: Science, Public Debate and Policy making” in 
December 2003. The objective of the conference was to explore the effect of human 
perception on risk assessment and risk analysis and its significance and implications in 
promoting key scientific paradigms underlying regulatory oversight and governance. 
The emergence of “Technology Platforms” is expected to add a new dimension of 
dynamism to societal dialogue by bringing together all interested stakeholders - research 
organisations, industry, regulators, user groups, etc. – around key technologies, in order to 
devise and implement a common strategy for the development, deployment and use of these 
technologies in Europe. 
The importance of research communication, openness and researchers contact with society 
has been recognised and Member States as well as the Commission have taken actions to 
identify measures and tools to improve communication. Within FP6 research communication 
to the general public is an integral part of the research projects.  
Priorities for future actions 
Commission and Member States 
►  to engage in exchange of experience in order to establish a more comprehensive strategy for 
communicating research. 
We can not neglect that at the same time as research in Life Science and Biotechnology is 
demonstrating its vast potential for improving quality of life, weapons engineered to attack 
humans, animals or plants is becoming an increasing concern. 
It is clear that a central component of the debate is to raise the awareness of the global 
scientific community also about this dual-use “tension” and the responsibility to mitigate any 
possible risks associated with research in Life Science and Biotechnology. As a first initiative 
to stimulate an international dialogue, the Commission organised a conference 3-4 February 
2004 on the “Ethical implications of scientific research on bioweapons and prevention of bio 
terrorism”. The participants appeared to agree that concerning the restriction of release of 
scientific results, the benefits of releasing scientific information outweighs the risk of its 
misuse.  
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Developing life sciences and biotechnology in harmony with ethical values and societal 
goals 
The immediate responsibility of the Commission is to ensure public trust and confidence in its 
research projects. The application of the ethical review system in the FP6 has been made 
more consistent and systematic for research project involving human beings, human tissue, 
private or personal data, genetic information and/or animals. A reporting system has improved 
the governance and transparency of such EC funded research. It also acts as a mean for raising 
the awareness of research regarding ethical issues. 
Several specific actions have been undertaken in the context of implementation of the Science 
and Society action plan
20. In particular, a Forum of the Presidents of the National Ethics 
Councils has been established, allowing for an exchange of positions and views about 
important topics of bioethics and ethics in research in Europe. A directory of local ethics 
committees has been collected in the 33 countries of ERA. 
Priorities for future actions 
Commission 
► to  establish  a  documentation and information system on ethics in research in 2005. The 
system will be based on a FP5 project and a feasibility study launched in February 2004. It will 
provide information on the different legislation, debates and important literature in ERA 
The European Group on Life Sciences (EGLS) has been continuing its activities towards 
facilitating broad communication and societal dialogue on life sciences and biotechnology. 
An Encounter - Modern Biology and Visions of Humanity - gathering scientists, humanists 
and scholars from the arts to reflect on the reciprocal impact of life sciences, our cultures and 
societies, took place on 22-23 March 2004.  
In accordance with the statements to the minutes of the Council of 30 September 2003 on the 
specific programme “Integrating and strengthening the European Research Area” and in order 
to contribute to the current debate within the context of deciding on the funding of human 
embryonic stem cell research under the FP6, the following steps were taken by the 
Commission: 
                                                 
20 COM(2001)714  final  
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–  a report on human embryonic stem cell research was published on 3 April 
2003 (SEC(2003) 441); 
–  an inter-institutional seminar was organised on 24 April 2003 on the same 
subject; 
–  procedural modalities for research activities involving banked or 
isolated human embryonic stem cells in culture to be funded under FP6 
were adopted by the Commission on 11 November 2003 ( C(2003) 2952). 
These modalities clarify the procedure which the Commission will follow 
when evaluating selecting and supporting research projects involving such 
research activities; 
–  a proposal, based on Article 166(4) of the Treaty, establishing further 
guidelines on the principles for deciding on possible Community funding of 
research projects involving in particular the use of human embryonic stem 
cells within the framework of FP6, was submitted to the Institutions in July 
2003. Although supported by the European Parliament, these guidelines 
were not adopted by the Council. 
Confidence in science-based regulatory oversight 
Review of the pharmaceutical legislation 
The review of the pharmaceutical legislation was adopted on 11 March 2004. There are three 
elements of particular importance for the development of stronger entrepreneurial 
biotechnology, namely a series of provisions to develop and reinforce the system of giving 
scientific advice through the creation of expert panels and permanent working groups in the 
EMEA, the introduction of a fast-track marketing authorisation procedure for products with a 
major public health interest for European patients, and a conditional marketing authorisation.  
In parallel, the G10 process, launched in 2001, has already passed some significant 
milestones. Following the Council Conclusions on the Communication
21, the G10 process has 
now entered its implementation phase. 
Most of the Recommendations will be implemented through existing EU programmes such as 
the Pharmaceutical Review, the FP6 and the Public Health Programme. However, it will be 
supplemented by specific exercises to take forward recommendations on benchmarking, 
patient information, pricing and relative effectiveness. To make progress in these areas will 
require both the Commission and Member States to take joint action building on the 
consensus developed through the G10 process. 
Genetically Modified Organisms (GMOs) legislation 
On 28 January 2004, the Commission held an orientation debate on GMOs and related issues 
to take stock of the progress made in recent years in building a comprehensive EU regulatory 
framework on GMOs, in close dialogue with Member States and all stakeholders
22. 
                                                 
21  Communication from the Commission to the Council, the European Parliament, the Economic and 
Social Committee and the Committee of the Regions ‘A stronger European-based Pharmaceutical 
Industry for the Benefit of the Patient – A Call for Action COM(2003)383 final  
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Regulatory Framework on GMOs 
–  Directive 2001/18/EC
23, which provides for a more complete authorisation procedure for 
GMOs, has been fully applicable since 17 October 2002;  
–  the two new Regulations on genetically modified organisms (GMOs), establishing a 
comprehensive Community system to trace and label GMOs and to regulate the placing on 
the market and labelling of GM food and feed, have been adopted by the Council and EP 
and will be fully applicable by April 2004
24; Regulation (EC) No 1829/2003 covers GMOs 
for food and feed use as well as food and feed containing, consisting of, or produced from 
GMOs. The Regulation is based on the “one door-one key” principle. Thus, it is possible to 
file a single application for obtaining both the authorisation for the deliberate release of a 
GMO into the environment, under the criteria laid down in Directive 2001/18/EC and the 
authorisation for use of this GMO in food and/or feed under the criteria laid down in 
Regulation 1829/2003. This authorisation, valid throughout the Community, is granted 
subject to a single risk assessment process under the responsibility of the European Food 
Safety Authority and a single risk management process involving the Commission and the 
Member States through a regulatory committee procedure. 
The Regulation extends the labelling provisions to all genetically modified food and feed 
irrespective of the detectability of DNA and protein. The applicability of this requirement 
is ensured through the provisions laid down in Regulation 1830/2003 on traceability and 
labelling. In order to ensure the feasibility and practicability of the Regulation, provisions 
regarding derogation for adventitious or technically unavoidable presence of GMOs in 
food/feed have been foreseen. 
–  a number of implementing measures and guidelines for the above legislation have been 
adopted or are in preparation with a view to completing and ensuring full applicability of 
the new regulatory framework by April 2004; 
–  Regulation (EC) No 1946/2003 on transboundary movements of GMOs was adopted on 
15 July 2003 by the Council and the EP and is applicable as of 25 November 2003
 25. This 
Regulation complements the above regulatory framework on GMOs, in particular as regards 
exports, and aligns it with the provisions of the Cartagena Protocol on Biosafety, which 
entered into force on 11 September 2003. 
On that occasion, the Commission reconfirmed its approach on GMO authorisation 
procedures and agreed on a number of actions in the short term. 
The Commission now expects more active co-operation from all Member States in ensuring 
correct implementation of the new legislation governing GMOs, which they themselves 
demanded—and subsequently committed themselves to. 
Regrettably, to date only seven Member States have fully communicated their 
implementation measures for Directive 2001/18/EC
26. These are currently being assessed by 
                                                                                                                                                          
22  Communication to the Commission available at: 
http://www.europa.eu.int/rapid/start/cgi/guesten.ksh?p_action.gettxt=gt&doc=IP/04/118|0|RAPID&lg=
EN&display= 
23  OJ L 106, 17.4.2001, p.1. 
24  Regulation (EC) No 1829/2003 of the EP and of the Council of 22.9.2003 on genetically modified food 
and feed (OJ L 268, 18.10.2003, p.1; Regulation (EC) No 1830/2003 concerning the traceability and 
labelling of genetically modified organisms and the traceability of food and feed products produced 
from genetically modified organisms and amending Directive 2001/18/EC (OJ L 268, 18.10.2003, p.24) 
25  Regulation (EC) No 1946/2003 of the European Parliament and of the Council on the transboundary 
movement of GMOs (OJ L 287, 5.11.2003, p.1). 
26  UK, Denmark, Sweden, Portugal, Italy, Spain and Ireland.  
 19       
the Commission for their conformity. The Commission has referred the eight Member States 
that have still not adopted national transposition measures to the European Court of Justice. 
Priorities for future actions 
Member States 
►  to fully and swiftly transpose and implement Directive 2001/18/EC, 
►  to withdraw national measures invoked under the novel food regulations and under environmental 
legislation and to lift the relevant restrictions. 
Commission 
►  to complete the adoption of implementing measures and guidelines, 
►  to adopt labelling thresholds for the adventitious or technically unavoidable presence of authorised 
GM seeds in seeds of non-GM varieties under Article 21(2) of Directive 2001/18/EC. Similar 
thresholds will then be adopted under the Seeds Directives. 
Co-existence of GM crops with conventional and organic crops 
The cultivation of GM crops may have implications for the organisation of agricultural 
production. Co-existence refers to the ability of farmers to make a practical choice between 
conventional, organic and GM crop production in compliance with the legal obligations for 
labelling and purity standards. 
At its meeting on 5 March 2003, the Commission agreed that it should be up to the Member 
States to develop and implement management measures concerning co-existence, in 
accordance with the subsidiarity principle. The Round Table hosted by the Commission on 
24 April 2003 to examine the latest research results on the co-existence of GM and 
non-GM crops concluded that any approach needs to take account of the diversity in regional 
conditions, which argues against a unified Community approach towards co-existence. 
In the light of the above, on 23 July 2003, the Commission adopted a Recommendation 
setting out guidelines for the development of national strategies and best practices to 
ensure the co-existence
27 of GMOs with conventional and organic farming.  
The guidelines provide a list of general principles and elements for the development of national 
strategies and best practices as well as an indicative catalogue of measures that can be used to 
reduce or avoid the accidental mixture of GM and non-GM crops. The basic principle 
underlying the guidelines is that no form of agriculture, be it GM, conventional or organic, 
should be excluded in the EU in the future. Measures for co-existence should be efficient, 
cost-effective and proportionate and should not go beyond what is necessary to ensure that the 
adventitious presence of GMOs stays below the tolerance thresholds. 
The subsidiarity approach was endorsed by the Council and the European Parliament last 
July, when a new Article specifically authorising Member States to take appropriate measures 
to avoid “the unintended presence of GMOs in other products” was introduced in the 
environmental legislation (i.e. Article 26(a) of Directive 2001/18/EC on the deliberate release 
into the environment of GMOs). This Article also establishes that the role of the Commission 
is to gather and co-ordinate information and observe developments regarding co-existence in 
                                                 
27  Commission Recommendation 2003/556/EC on co-existence.  
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the Member States. In the Recommendation itself, the Commission committed itself to 
coordinating the exchange of information on measures, experiences and best practices 
supplied by the Member States. 
Many Member States are now seeking clarification as to what sort of co-existence measures 
would be legally acceptable.  
The Commission recommendation on co-existence was discussed in the Council of 
Agricultural Ministers of 29 September 2003, where Member States and acceding countries 
were split between supporting the subsidiarity approach and requesting that rules on co-
existence be established at Community level.  
Furthermore, on 18 December 2003, the EP plenary adopted an own-initiative report calling 
for uniform and binding rules on co-existence to be established at Community level, including 
Community-wide liability rules and insurance in respect of possible economic damage in 
connection with co-existence. 
Several Member States have been considering their policies on co-existence. Following public 
debate, science review and studies on the costs and benefits of GM crops. National debates 
were organised, amongst other initiatives, in the UK
28 and Denmark. National co-existence 
strategies are in advanced stage of adoption by Denmark and Germany.  
While a number of draft “co-existence” measures have already been notified to the 
Commission, the Commission is also aware of non-notified co-existence measures, taken at 
national, regional or local level, which might contradict Community legislation and could 
prompt infringement procedures. 
Priorities for future actions 
Member States 
►  to ensure an exchange of information on successful approaches and best practices and to notify 
national or regional measures on co-existence to the Commission. 
Commission 
►  to enhance its co-ordination role as defined in Directive 2001/18/EC, in order to smooth any 
potential problems linked to the development of co-existence strategies by Member States, 
►  to report to the Council and the European Parliament, using information from the Member States, 
on the experience gained in the Member States concerning the implementation of measures to 
address co-existence, including, where appropriate, an evaluation and assessment of all possible 
and necessary steps to be taken. 
3.3.  Europe in the world - responding to global challenges 
A European Agenda for international cooperation 
The Commission has continued to play an active role in developing international guidelines, 
standards and recommendations in the relevant sectors and within established international 
forums such as UN-organisations, OECD, the Council of Europe Steering Committee on 
Bioethics. Now that the Community has become a full member of the Codex Alimentarius 
                                                 
28  Further details are available on the "GM Nation" web site - http://www.gmnation.org.uk/  
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Commission, the Commission intends to contribute in full to the development of Codex 
guidelines relating to food produced from biotechnology. 
An important example of this commitment is the Commission's role in the works of the 
Cartagena Protocol on Biosafety which entered into force on 11 September 2003. At the First 
Meeting of the Parties to the Cartagena Protocol, held in Kuala Lumpur (23-27 February 
2004), a consensus was reached in relation to documentation requirements for the 
transboundary movement of GMOs, on an action plan to help developing countries 
implementing the Protocol, on a compliance mechanism and on a fully operational internet-
based Clearing House for the international exchange of information related to GMOs.  
At the same time, it has promoted and participated in initiatives aimed at improving dialogue 
with our trade partners towards a better understanding of the issues relating to the application 
of biotechnology and its governance.  
The Commission actively participated in the UNIDO Global Biotechnology Forum, which 
took place in Chile 2-5 March 2004.  
Constructive and fruitful bilateral dialogues with Japan, which, like the EU, also launched a 
strategy for life sciences and biotechnology in 2002, have taken place within the framework 
of the EU-Japan Industrial Policy Dialogue and within the industry-led EU-Japan Business 
Dialogue Round Table.  
However, on 29 August 2003 the long-standing divergence of views between the EU and 
some of its trading partners culminated in the establishment of a WTO panel, at the request 
of the US, Canada and Argentina, to rule on the matter of GMOs.  
The Commission has always made it clear that a WTO challenge is an inappropriate and 
regrettable move. At a time when most countries are developing appropriate legal frameworks 
to deal with the modern techniques of genetic modification, the decision to start a WTO case 
is in stark contrast with the spirit of co-operation that should herald the global trend towards 
more comprehensive and better regulation. While it is only right and proper for states to raise 
their legitimate trade concerns through the appropriate channels, the Commission views the 
WTO challenge on GMOs as an obstacle to the search for common, trade-enhancing 
approaches to biotechnology. 
The Commission will continue to promote international and bilateral cooperation in the field 
of biotechnology. The Commission considers that there are important political and technical 
issues that need to be addressed at international level and remains committed to discussing 
those issues with any parties willing to enter into a constructive dialogue. 
Europe’s responsibilities towards the developing world 
Agriculture and Genetic Resources 
The EC is the main contributor to the new Consultative Group on International 
Agricultural Research (CGIAR) Challenge Program “Unlocking Genetic Diversity in 
Crops for the Resource-Poor”, which is developing a unique platform involving public, 
private and civil society partners for accessing and developing new genetic resources using 
new molecular technologies and traditional means. Through the programme, an 
unprecedented array of genomic and genetic resources, ready for direct use in plant 
improvement, will be made available as public goods in the form of enabling technologies  
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and intermediate products for crop improvement programmes. Tolerance to drought will be 
the first issue to be considered for proof of concept. 
Health 
In February 2003, the Commission adopted a Communication reviewing progress achieved 
under the Programme for Action entitled "Accelerated action on HIV/AIDS, malaria and 
TB in the context of poverty reduction" and putting forward recommendations for further 
actions
29. 
In terms of ‘increasing investment in research and development’, substantial resources have 
been allocated from the Research Framework Programmes for HIV/AIDS, malaria and TB 
research, including the establishment of the new European and Developing Countries 
Clinical Trials Partnership (EDCTP) initiative which is the first joint programme to bring 
together the efforts of several Member States aimed at developing and evaluating new 
vaccines and drugs against those diseases. The EDCTP clearly constitutes a new step forward 
as it provides a unified voice to represent European research contributions in the fight against 
the three diseases in developing countries. Additional direct and indirect incentives for 
research and development of specific global public goods to fight the three diseases will 
require primary focus in the coming years. 
European and Developing Countries Clinical Trials Partnership (EDCTP) 
The EDTCP was adopted in June 2003 and will be fully operational during the first half of 
2004. It is an independent legal entity with its own operational procedures, including calls for 
proposals and appropriate selection of the clinical trials to be fully or partially funded. The 
EDCTP has a target budget of € 600 million. The Community will contribute one third of the 
budget via the 6
th FP, whereas another € 200 million will be provided by Member States and 
Norway. The remaining € 200 million will be sought from private sources, R&D industry, 
foundations, charities and Community development funds (e.g. EDF).  
A carefully balanced management structure ensures that developing countries are equal partners 
in strategic decisions.  
In addition, financial support for research projects under FP6 in the area of poverty-related 
diseases (HIV/AIDS, malaria and tuberculosis) is significantly increased. Support will be 
given to Preclinical and early clinical testing of new drugs, vaccines and microbicides for 
HIV/AIDS, malaria and TB. Support will be given in particular to large research consortia 
that integrate different disciplines and approaches and can generate a critical mass between 
the different players involved. Active participation of partners from endemic, developing 
countries is specifically encouraged. The first call for proposals under FP6 resulted in funding 
projects, among others, for the development of a new TB vaccine and for preclinical testing of 
vaccines and microbicides targeting HIV. 
Finally, the Commission will also continue to support research on further neglected tropical 
diseases, such as ''sleeping sickness''. 
                                                 
29 COM(2003)93  final  
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3.4.  Newly Emerging issues 
Tissue engineering 
Tissue engineering is a, young and emerging multidisciplinary biotechnology sector which 
promises to change medical practice profoundly, regenerating diseased tissues and organs 
instead of just repairing them. However, as highlighted in a report of the Commission’s Joint 
Research Centre (JRC)
30, the size of the tissue engineering market and the commercial range 
of applications is still in its infant phase, mostly because the first products (skin, cartilage and 
bone) have “conventional” alternatives firmly rooted in the market. This situation may change 
if tissue engineering begins to produce applications with life saving properties, and targets 
conditions with no conventional counterparts. Several significant scientific and technological 
challenges still have to be met. Meanwhile the regulatory framework applied differs from 
Member State to Member State. The lack of a clear and uniform regulatory framework leads 
to legal uncertainty and to a fragmentation of this emerging market. This might in the long 
term undermine EU competitiveness in the sector. 
In its report, the CBAG has called for new market authorisation legislation for 
biotechnology-based healthcare applications that are not considered medicines or medical 
devices, such as human tissue engineering. 
Priorities for future actions 
Commission 
►  to prepare legislation to harmonise the authorisation procedures for marketing products/processes 
from human tissue engineering, while guaranteeing a high level of protection for patients, to be 
presented to Parliament and Council before summer 2004. 
Genetic testing 
Genetic testing is a most relevant example of leading-edge research and development - 
showing potential for the benefit of society - and at the same time having policy implications 
for research, public health, regulation, fundamental rights, ethics and international 
cooperation beyond the EU.  
A growing number of laboratories in Europe and the world are offering a wide and varied 
array of genetic testing and analysis services. These practices are becoming increasingly 
frequent, highly variable in quality, and available across national boundaries and some genetic 
tests are becoming the subject of uncontrolled “mass marketing”, including via the Internet. In 
a recent statement, the European Group on Ethics (EGE) warned against the risks of 
advertising genetic testing via the Internet
31. 
As yet no EU Member State is self-sufficient in testing for rare diseases, and cross-border co-
operation remains suboptimal, highlighting the need to encourage a broader exchange of 
information and samples though trans-national networking, which is essential for ensuring the 
development of tests as well as for accessibility to genetic testing. 
                                                 
30  The JRC report “Human tissue-engineered products. Today’s markets and future prospects” may be 
downloaded at: http://www.jrc.es 
31 http://europa.eu.int/comm/european_group_ethics/docs/statgentest-en.pdf  
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Although genetics specialists and professional organisations have made many moves to 
promote quality assessment, genetic testing services are provided under widely varying 
conditions and regulatory frameworks in different countries, including in the EU. The recent 
prospective study from the Commission’s JRC
32 identifies shortcomings and measures to 
ensure the highest quality of such services, including 
►  harmonised quality control genetic tests and the counselling that accompanies them,  
►  development of a common range of certified reference materials,  
►  better cross-border co-operation, and  
►  the establishment of a European database of genetic testing centres 
In view of the increasing international trade in genetic tests and services (60% of genetic test 
specimens are circulate across borders), and the policy issues this raises, the Commission and 
the OECD jointly organised an  EC-OECD Colloquium on Genetic Testing Quality 
Assurance, held in Brussels on 6 October 2003. As a result of the discussions the OECD is 
now considering drafting “codes of conducts” for quality assurance of genetic testing.  
A high level expert group “ETAN-STRATA”, composed of representatives from 
pharmaceutical companies, NGOs (in particular patient organisations), scientists and social 
and legal experts has been discussing the ethical, legal and social implications of genetic 
testing for a year now. A final report including actions and recommendations to be undertaken 
will be published in April 2004. It should provide the basis for a wider discussion on these 
recommendations at a stakeholder conference planned for 6-7 May 2004.  
Furthermore, the Commission organised, in collaboration with the “European Association of 
Mutualities” a conference on the impact of genetic testing on the heath insurance system 
“New genetic applications and access to healthcare” in Brussels, 24-25 March 2004. 
Following a request from the Commission, the EGE gave an opinion in July 2003 on genetic 
testing in the workplace
33, recommending that legal measures should be taken at EU level to 
preserve the confidentiality of genetic data, including in the event of transborder movement of 
employees/employers, i.e. in the context of free movement of workers within the EU. A 
proposal for a Directive on the protection of workers’ personal data in the employment 
context is currently under preparation. 
The various activities undertaken regarding genetic testing at European and international level 
have indicated the need for a co-ordinated approach to this emerging field. 
                                                 
32  The JRC report “Towards quality assurance and harmonisation of genetic testing services in the EU” 
may be downloaded at: http://www.jrc.es 
33  The EGE opinion “Ethical aspects of genetic testing in the workplace” may be downloaded at: 
http://www.europa.eu.int/comm/european_group_ethics/index_en.htm  
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Priorities for future actions 
Commission and Member States 
►  to engage in EU-wide co-ordination of efforts to ensure the highest quality of genetic testing in 
the EU and beyond EU-25, 
► to  establish  EU-wide networking of national centres for exchanges of information regarding 
quality assurance of genetic testing, including training activities, and EU-wide networking for 
genetic testing of rare diseases. 
Animal biotechnology 
Animal biotechnology, like many other categories of biotechnology, covers a wide range of 
applications. As much as any other category, it may become economically significant but also 
controversial. Its technological development seems to be approaching the point where the 
commercialisation of startling innovations is starting to attract public attention. 
The EU’s case-by-case approach to the deliberate release of GMOs into the environment 
applies to both GM animals and GM plants. Thus authorisation to place any GM variety of 
animal species on the market would require a rigorous scientific assessment of possible risks 
to the environment and human health before the marketing of the animal is authorised. 
Similarly, the marketing of food and feed products produced from such GM animals would be 
subject to cases by cases authorisation based on a rigorous scientific risk assessment. The 
existing regulatory framework for GMOs appears to be satisfactory at EU level. 
Another emerging issue is the application of cloning technology in animals, and in particular 
the introduction of products obtained from cloned livestock into the food chain. It may raise 
ethical and social and safety concerns. 
Priorities for future actions 
Commission 
►  to launch initiatives on the potential benefits, risks and possible new policy issues associated with 
the application of animal cloning, including a prospective study. 
4.  OVERALL CONCLUSIONS 
Since last year’s report, further progress has been made on implementation of the Strategy 
and roadmap on Life Sciences and Biotechnology. The review of the Pharmaceutical 
legislation and the GMO regulatory framework have both been completed, guidelines on 
coexistence in agriculture have been published, and FP6 provides a major incentive for 
research in this area. 
However, there is no doubt that there is a lot to be done to improve the situation for European 
biotechnology and its competitiveness: 
–  public and private investment in research needs urgently to be increased, 
–  biotechnology companies’ access to finance needs to be further improved.  
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The next stage in the strategy is for the various authorities and organisations to make 
commitments and to begin delivering the new policy measures in accordance with the 
responsibilities set out in the action plan.  
This involves not only the European Institutions; it also seeks to include measures that are 
more the responsibility of the Member States and other public authorities and the private 
sector. The Commission is directly responsible for some actions but it is also determined to do 
what it can to keep up the general momentum and to play a facilitating role. For their part, the 
Member States are now actively working with the Commission to flesh out the details of how 
some of the actions should be implemented. However, they also still need to make progress 
on the implementation of measures to which they are already committed.  
One major example is intellectual property, where delays have occurred in the 
implementation of Directive 98/44/EC, on the legal protection of biotechnological inventions. 
The slow progress in adopting a practical Community Patent Regulation is also a source of 
concern. 
Member States and the Commission will also have to continue their collaboration to ensure 
that the follow up of the G10 process moves forward effectively in all its aspects. 
More active co-operation from all Member States is also needed in the implementation of 
the new legislation governing GMOs. Having demanded—and subsequently committed 
themselves to—a more rigorous framework, it is now imperative that all Member States 
should implement the basic Directive 2001/18/EC on the authorised release of GMOs into the 
environment and the two regulations on traceability/labelling and on GM/food and feed.  
Against the background of the renewed political debate on the Lisbon agenda of task to 
revamp Europe’s competitive position, there is an acknowledged need to step up the measures 
to fulfil the Lisbon commitments. The Biotechnology Strategy includes many subjects and 
stakeholders and the Union has to ensure that the coherence of its efforts is maintained. This 
calls for strengthened coordination and cooperation between Member States and the 
Commission, with the aim of improving Europe’s competitiveness. The Commission 
suggests that on the basis of this Report, the Council discuss the state of implementation and 
what further measures may usefully be taken to achieve these objectives. Against this 
background, the Commission also proposes to reinforce the role of the existing Biotechnology 
network with Member States. 